• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

简介:肯尼亚多地点血清学监测(KEMIS)合作项目。

Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration.

作者信息

Kagucia E Wangeci, Voller Shirine, Ziraba Abdhalah K, Bigogo Godfrey, Munywoki Patrick K, Makobu Kimani, Nokes D James, Nyagwange James, Orlendo Cameline, Akech Donald, Sigilai Antipa, Onyango Clayton, Juma Bonventure, Herman-Roloff Amy, Munyua Peninah, Apondi Caroline, Lidechi Shirley, Audi Allan, Ouma Alice, Aol George, Misore Thomas, Nasimiyu Caroline, Onyango Dickens, Lo Terrence, Kasera Kadondi, Jalang'o Rose, Kingwara Leonard, Adetifa Ifedayo, Etyang Anthony O, Warimwe George, Agweyu Ambrose, Scott J Anthony G

机构信息

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

出版信息

Gates Open Res. 2025 Feb 27;8:60. doi: 10.12688/gatesopenres.15569.2. eCollection 2024.

DOI:10.12688/gatesopenres.15569.2
PMID:40496022
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12149407/
Abstract

The Kenya Multi Site Serosurveillance (KEMIS) collaboration set out to implement an integrated, nationally representative, population-based program of serological surveillance for past infection for a number of important infectious diseases in Kenya. The project started in December 2021 and built on a portfolio of SARS-CoV-2 research conducted in 2020 and 2021. In this profile paper, we describe the background of the KEMIS collaboration, its aim and objectives, the Health and Demographic Surveillance System sites that were involved in data collection, and the key activities undertaken. We also explain how we established governance and management of the KEMIS collaboration, and reflect on opportunities, challenges, lessons learned, and future directions.

摘要

肯尼亚多地点血清学监测(KEMIS)合作项目旨在实施一项综合的、具有全国代表性的、基于人群的血清学监测计划,以检测肯尼亚多种重要传染病的既往感染情况。该项目于2021年12月启动,以2020年和2021年开展的一系列新冠病毒研究为基础。在这篇简介文章中,我们描述了KEMIS合作项目的背景、目标、参与数据收集的健康与人口监测系统站点,以及开展的关键活动。我们还解释了如何建立KEMIS合作项目的治理和管理机制,并思考了机遇、挑战、经验教训及未来方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3535/12149558/27e388af7aa2/gatesopenres-8-17710-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3535/12149558/bc283e2441f5/gatesopenres-8-17710-g0000.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3535/12149558/27e388af7aa2/gatesopenres-8-17710-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3535/12149558/bc283e2441f5/gatesopenres-8-17710-g0000.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3535/12149558/27e388af7aa2/gatesopenres-8-17710-g0001.jpg

相似文献

1
Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration.简介:肯尼亚多地点血清学监测(KEMIS)合作项目。
Gates Open Res. 2025 Feb 27;8:60. doi: 10.12688/gatesopenres.15569.2. eCollection 2024.
2
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
3
Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population.肯尼亚人群中接种疫苗和未接种疫苗患者体内 SARS-CoV-2 宿主内基因进化特征分析
J Virol. 2025 Jun 17;99(6):e0048225. doi: 10.1128/jvi.00482-25. Epub 2025 May 6.
4
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
5
Application of a high-resolution melt assay for monitoring SARS-CoV-2 variants in Burkina Faso and Kenya.高分辨率熔解分析在布基纳法索和肯尼亚监测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体中的应用。
mSphere. 2025 Jun 25;10(6):e0002725. doi: 10.1128/msphere.00027-25. Epub 2025 May 29.
6
Community views on mass drug administration for soil-transmitted helminths: a qualitative evidence synthesis.社区对土壤传播蠕虫群体药物给药的看法:定性证据综合分析
Cochrane Database Syst Rev. 2025 Jun 20;6:CD015794. doi: 10.1002/14651858.CD015794.pub2.
7
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
8
Sero-prevalence of SARS-CoV-2 antibodies in Ethiopia: Results of the National Population Based Survey, 2021.埃塞俄比亚2019冠状病毒病抗体血清流行率:2021年全国人口调查结果
PLoS One. 2025 May 6;20(5):e0313791. doi: 10.1371/journal.pone.0313791. eCollection 2025.
9
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
10
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

本文引用的文献

1
Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021.2021年3月和6月,在肯尼亚两个疫苗接种率低、人口结构不同的人群中,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的异质性传播和血清阳性率
Gates Open Res. 2023 Oct 9;7:101. doi: 10.12688/gatesopenres.14684.2. eCollection 2023.
2
SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.SARS-CoV-2 血清流行率及其对人群免疫力的影响:来自肯尼亚两个健康和人口监测系统站点的证据,2022 年 2 月至 12 月。
Influenza Other Respir Viruses. 2023 Sep;17(9):e13173. doi: 10.1111/irv.13173.
3
Learning from serosurveillance for SARS-CoV-2 to inform pandemic preparedness and response.
从新冠病毒血清学监测中汲取经验,为大流行防范与应对提供信息。
Lancet. 2023 Jul 29;402(10399):356-358. doi: 10.1016/S0140-6736(23)00964-9. Epub 2023 May 26.
4
SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021.2020年12月至2021年5月,肯尼亚三个健康与人口监测点的新冠病毒血清流行率
PLOS Glob Public Health. 2022 Aug 18;2(8):e0000883. doi: 10.1371/journal.pgph.0000883. eCollection 2022.
5
Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance.SARS-CoV-2 血清流行率结果报告的及时性及其在传染病监测中的应用。
Epidemics. 2022 Dec;41:100645. doi: 10.1016/j.epidem.2022.100645. Epub 2022 Oct 20.
6
Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21.肯尼亚三家转诊医院产前护理诊所的 SARS-CoV-2 IgG 血清监测:2020-21 年重复横断面调查。
PLoS One. 2022 Oct 14;17(10):e0265478. doi: 10.1371/journal.pone.0265478. eCollection 2022.
7
Building an integrated serosurveillance platform to inform public health interventions: Insights from an experts' meeting on serum biomarkers.建立一个综合的血清学监测平台,为公共卫生干预措施提供信息:血清生物标志物专家会议的见解。
PLoS Negl Trop Dis. 2022 Oct 6;16(10):e0010657. doi: 10.1371/journal.pntd.0010657. eCollection 2022 Oct.
8
Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data.基于血清学和聚合酶链反应检测数据揭示肯尼亚新冠疫情第一波的波及范围。
Wellcome Open Res. 2022 Sep 22;6:127. doi: 10.12688/wellcomeopenres.16748.3. eCollection 2021.
9
Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya.肯尼亚 COVID-19 疫苗接种的流行病学影响和成本效益分析。
BMJ Glob Health. 2022 Aug;7(8). doi: 10.1136/bmjgh-2022-009430.
10
Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi, Kenya, December 2020.2020 年 12 月,肯尼亚内罗毕一个城市非正规住区的 SARS-CoV-2 感染血清阳性率和危险因素。
F1000Res. 2021 Aug 26;10:853. doi: 10.12688/f1000research.72914.2. eCollection 2021.